|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.37 USD | -0.88% |
|
-7.13% | +31.46% |
| Feb. 09 | Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $17 From $21, Maintains Perform Rating | MT |
| Feb. 07 | Transcript : Enanta Pharmaceuticals, Inc., Q1 2024 Earnings Call, Feb 07, 2024 |
Enanta Pharmaceuticals, Inc. reported earnings results for the first quarter ended December 31, 2023. For the first quarter, the company reported sales was USD 18 million compared to USD 23.59 million a year ago. Net loss was USD 33.41 million compared to USD 28.99 million a year ago.
Basic loss per share from continuing operations was USD 1.58 compared to USD 1.39 a year ago. Diluted loss per share from continuing operations was USD 1.58 compared to USD 1.39 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +31.46% | 262M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
ENANTA PHARMACEUTICALS, INC. 
